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INTRODUCTION
Sundown syndrome, also known as sundowning, is a com-
mon clinical phenomenon manifested by the emergence or 
increment of neuropsychiatric symptoms in the late afternoon, 
evening or at night. It particularly occurs among cognitively 
impaired, demented, or institutionalized elderly patients.
1,2 
Sundowning is a descriptive term and not a psychiatric diag-
nosis formally recognized in the DSM-IV-TR. Despite the lack 
of a formal recognition, “sundowning” is broadly used to de-
scribe a set of neuropsychiatric symptoms occurring in elder-
ly patients with or without dementia at the time of sunset, at 
evening, or at night. These behaviors represent a wide variety 
of symptoms such as confusion, disorientation, anxiety, agi-
tation, aggression, pacing, wandering, resistance to redirec-
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tion, screaming, yelling and so forth. Some of these behaviors 
may not be specific to sundowning and can be the manifesta-
tion of dementia, delirium, Parkinson’s disease, and sleep dis-
turbances. 
However, what distinguishes sundowning from above men-
tioned conditions is that persons with sundown syndrome 
characteristically show disruptive behaviors specifically in the 
late afternoon, in the evening, or at night.
2 They can be very 
challenging to caregivers to deal with those symptoms. One 
study indicates that agitation from sundown syndrome is a 
common cause of institutionalization of older patients suffer-
ing from dementia.
3 Other clinical features of sundowning in-
clude mood swings, abnormally demanding attitude, suspi-
ciousness, and visual and auditory hallucinations in the late 
afternoon and evening.
4 
Geriatric clinicians have frequently observed that some de-
mented individuals show increased agitation, restlessness and 
confusion in late afternoon, evening or night. This has popul-
arly been named “sundowning” or “sundown syndrome”. Cli-
nical observations on sundowning are multiple in medical 
literatures, but they have failed to arrive at a consensus as to its 
definition. They also disagree on almost every aspect of the syn-
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drome.
5 Research data related to this unique clinical pheno-
menon are limited to date. Cameron described this phenom-
enon in 1941 as “nocturnal delirium” and “delirium and agi-
tation within one hour of darkness”.
1 Prinz and Raskind
6 de-
fined sundowning as a marked increase in confusion, disori-
entation and possibly agitation in an elderly or severely cog-
nitively impaired subject at sunset or when daylight is reduced. 
Other clinical manifestations associated with sundowning are 
screaming, delusional thinking, moaning and wandering.
6 
Volicer et al.
4 defined sundowning as “the appearance or ex-
acerbation of behavioral disturbances associated with the af-
ternoon and/or evening hours”. Sadock described sundown-
ing as “a syndrome in older persons that usually occurs at 
night and is characterized by drowsiness, confusion, ataxia, 
and falling as the result of being overly sedated with medica-
tions”.
7 According to Bliwise, the term ”sundowning” was used 
in geriatric medicine to describe “the phenomenon of agita-
tion seemingly caused by, or at least strongly associated with 
darkness”.
8 Several researchers have found no clinical correla-
tion between exacerbation of behavioral abnormalities and 
circadian rhythm, and even question the existence of sundown-
ing.
9-12 They consider the disruptive behavior in demented pa-
tients later during the day to be rather an exacerbation of ex-
isting day time behavioral abnormalities and new symptoms 
occurring primarily in the late afternoon. Also, agitated beha-
vior of institutionalized patients has greater impact on nurs-
ing home staff in the evening.
9-12 Although other investigators 
demonstrated a great variability in the peak time of behavior-
al worsening, they all reported the maximal behavioral dis-
ruption sometime in the later afternoon or evening.
1,13
It is difficult to differentiate wide variety of temporal beha-
vioral disruptions in demented patients, and their correlation 
with other non-circadian rhythm related factors. Nevertheless, 
there is enough evidence in neurologic and psychiatric litera-
ture to suggest existence of a sundowning-type phenomenon 
in demented or cognitively impaired individuals, which ac-
cording to literature data includes a constellation of emotion-
al, cognitive, behavioral, and motor dysfunction.
1,2,4,5,9,13-20 
METHODS
A systematic search of the medical literature published in 
English between 1940 and 2010 performed using Pub Med, 
Medline, and other databases and sources. Search terms in-
cluded: sundowning, sundowning syndrome, sundown syn-
drome, and dementia. All literature on definition, epidemiol-
ogy, etiology, risk factors, diagnosis, differential diagnosis, tr-
eatment, prognosis, and prevention of sundowning syndrome 
were retrieved. 
RESULTS
Epidemiology
Currently, there is sparse literature on epidemiology of sun-
down syndrome. Data available on prevalence rates for sun-
down syndrome is variable. It depends on patient population 
and setting. According to the data from Alzheimer’s Associa-
tion in 2006, 2.4% to 25% patients diagnosed with Alzheimer’s 
disease (AD) had sundown syndrome.
21 Currently, there is no 
data on prevalence in gender, race and types of dementing dis-
orders. Although the prevalence of sundowning among pa-
tients with severe dementia is particularly high, this syndrome 
appears to affect virtually all patients with some degree of cog-
nitive impairment.
1,22 Sundowning is considered to be the se-
cond most common type of disruptive behavior in institutiona-
lized patients with dementia after wandering.
23 It appears to be 
endemic among institutionalized adults with dementia. Ev-
ans in her study at a nursing home facility found that 12.4% of 
elderly patients from general nursing home population dem-
onstrated significant changes in cognitive status in the late af-
ternoon.
13 Based on various data, the overall rates of sundown-
ing among patients with AD or other types of dementia ranges 
from 2.4% to 66%.
10,20-25 Gallagher-Thompson and associates, 
reported that the prevalence of sundowning as high as 66% 
among patients living at home.
26 Based on available data, it is 
impossible to do a valid comparative analysis of prevalence of 
sundowning syndrome in two different patient populations: 
institutionalized and non-institutionalized. The severity of 
cognitive impairment may be one of the important predispos-
ing factors in the development of sundown syndrome.
22 Vo-
licer at al.
4 reported that sundowning was also linked to the 
seasons with increased incidence in the fall or winter months 
due to a decrease in duration and amount of sunlight.
Etiology
The exact cause of sundown syndrome is unknown. Several 
theories have been proposed to understand the clinical phe-
nomenon of sundowning. Studies that have attempted to ex-
plain etiology of sundown syndrome can be divided into three 
major groups: physiological, psychological, and environmental.
22 
Sensory deprivation
One of the earliest studies on environmental factors and psy-
chophysiological variables in development of “nocturnal de-
lirium” was done by Cameron1 in 1941. Ancoli-Israel et al.
27 
indicated that patients with AD already have inadequate ex-
posure to amounts of light during the day. This finding for-
mulates the rationale for light therapy in demented patients. 
Morley
28 described a person with visual impairment due to 
macular degeneration, who repeatedly developed classic sun-N Khachiyants et al. 
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downing syndrome with changes in perception as day shifted 
into twilight. Among many factors, Smith
29 indicated that low 
lighting and increased shadows may aggravate late-day con-
fusion and sundowning. Duckett
22 has suggested significant 
differences in amount of light in various parts of the hospital 
that may not be readily apparent to the healthy eye. This sug-
gestion was discussed as the basis for modification of ambient 
light by “matching light readings attained from the day and 
evening hours.”
22
Circadian rhythm disorders
Majority of recent studies have focused on the important 
potential role of disordered circadian rhythm as an etiological 
factor of sundown syndrome in patients with dementia. Ac-
cording to these studies, sundowning as a nonspecific symp-
tom of different types of dementia may be a manifestation of 
specific path physiologic abnormalities that interfere with 
normal circadian rhythm and behavioral regulation.
4,20,30-34 In 
one study which investigated sundowning phenomenon in 
terms of disturbance in circadian rhythm or changes in sleep-
wake cycles, Feinberg et al.
34 reported that the elderly persons 
demonstrated an earlier onset of dream periods, as well as 
more frequent and abrupt awakenings episodes. They looked 
at nocturnal delirium as a transitional state from dreaming to 
wakefulness, and abrupt intrusion of dreams into a waking 
state. Evans
13 by reviewing the medical charts of a group of ins-
titutionalized elderly persons who were suffering from sun-
downing, has shown a significant relationship between sun-
downing and disturbances in circadian rhythms. Although 
the exact time, precise relationship between sundowning 
symptoms and late afternoon, or sunset hours are not deter-
mined yet, there is numerous evidence in the medical litera-
ture of the existence of a circadian rhythm for disrupted be-
haviors in many patients with AD that peaks in intensity late 
in the day.
8,13,35 Satlin et al.
20 reported that patients with severe 
AD have a greater total daily motor activity during night time, 
as well as less strictly circadian rhythm for motor activity, com-
pared to healthy elderly persons. Another companion study by 
the same group of researchers has revealed the opposite find-
ings that subjects with severe dementia had less diurnal mo-
tor activity and a higher intensity of nocturnal activity, com-
pared to control group. The study conducted by Evans
13 was 
consistent with above findings about the relationships be-
tween circadian rhythm disturbances and severity of cogni-
tive and behavioral deterioration in demented subjects. 
The central components of the physiological basis of the 
biological circadian rhythm include the suprachiasmatic nu-
cleus (SCN) and melatonin.
36 The SCN located in hypothala-
mus plays an important role in circadian rhythm regulation 
during awake state by producing an alerting signal; during 
sleep time SCN produces a sleep-inducing signal.
37 In humans, 
the circadian rhythm is responsible for sleep-wake cycling.
4 
The SCN acts as the major circadian pacemaker of the human 
body and influences several physiological functions includ-
ing the core body temperature, heart rate, and hormone se-
cretion.
38 Disruption of the circadian rhythms due to deteriora-
tion of the SCN observed in patients with AD may contribute 
to the development of sundowning syndrome.
10,36 The possible 
cause of the SCN deterioration is due to senile plaque forma-
tion that increases with age.
10 These pathological changes may 
theoretically explain disturbed sleep, agitation, confusion, 
and other symptoms of sundowning. It is suggested that the 
volume of SCN, as well as its cell number decreases in per-
sons between the ages of 80 and 100 years. Patients with de-
mentia of the Alzheimer’s type have more prominent abnorma-
lities in SCN.
36 Some researchers have found evidence of de-
terioration in the SCN at autopsy in patients with AD.
36,39 Hui-
tron-Resendiz et al.
40 demonstrated evidence for a relationship 
between AD pathology and circadian rhythm disturbance that 
has been revealed by studies in transgenic AD mouse models. 
According to this investigation, aged platelet-derived beta-am-
yloid precursor protein (PDAPP) transgenic mice exhibited 
marked sleep deficits in REM and non-REM sleep, as well as 
deficits in circadian distribution of sleep-wake states.
40 Data 
from other studies suggests a possible casual similarity to hu-
man sundowning behavior as they reported that the APP23 tr-
ansgenic mouse model of AD has shown increased motor ac-
tivation during the second half of the active phase, specifically 
at ages 6 months and 12 months.
41,42 Another important com-
ponent of circadian rhythm regulation is melatonin, a hormo-
ne produced by the pineal gland in darkness, and during sleep.
40 
Liu et al.
43 demonstrated that melatonin level has found to be 
decreased in the postmortem cerebrospinal fluid levels of pa-
tients with AD. This decrease causes deregulation in circadi-
an rhythm and lessens the neuroprotective effect on the SCN.
44 
Natural production of melatonin appears to decrease with 
aging, which could alter arteriolar wall in elderly persons.
45 
This explains the rationale for use of melatonin in AD.
40,46-48 
Sleep disorders
According to epidemiological studies, disturbances in du-
ration and quality of sleep increase with aging, and occur in 
approximately 38% of persons over 65-year-old.
49,50 36% ex-
perience difficulties in sleep initiation and 29% suffer from 
difficulties in sleep maintenance.
50 Hess 3 reported that al-
most half the patients with dementia experience clinically 
relevant sleep-wake disturbances. Jelicic et al.
51 demonstrated 
that subjective sleep disturbances in later life may potentially 
predict cognitive decline, and negatively correlate with cog-
nitive performance. Bliwise et al.
30 suggested that disturbances 278  Psychiatry Investig 2011;8:275-287
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in night sleep correlate with severity of dementia. Based on li-
terature, 34-43% of the patients with AD suffer from various 
sleep disturbances.
52,53 Sleep disturbances in AD, including 
disrupted chronobiology, sleep disordered breathing, and in-
creased daytime napping, are suggested to be multifactorial.
54 
Although the contribution of sleep disturbances in develop-
ment of late afternoon or early evening behavioral disruptions 
in dementia has not been established, there are some evid-
ence about possible relationship between them. According to 
Bliwise and associates,
54,55 increased incidence of sleep disor-
ders in patients with AD may explain nighttime worsening of 
behavior. REM-sleep disturbances, along with sleep apnea and 
dysregulation of SCN, are among suggested hypotheses for a 
possible physiological explanation of sundowning syndrome.
56 
According to this hypothesis, neuronal degeneration of choli-
nergic nucleus basalis of Meynert (NBM) neurons which mo-
dulate the activity of SCN and the induction of non-REM sleep, 
causes rest-activity cycle disturbances, and promotes sun-
downing in patients with AD.
54 It was reported that patients 
with dementia have various sleep architecture changes, includ-
ing an increase in stage I and II sleep, a decrease in stage III and 
stage IV, decreased consolidation of non-REM sleep, lower sle-
ep efficiency, an increased sleep fragmentation and episodes of 
awakenings, nocturnal wandering, an increase in daytime 
napping, as well as higher incidence of disruptive nocturnal be-
havior.
47-49 Martin et al.
57 reported that 42% of demented nurs-
ing home residents suffer from syndrome of sleep apnea. Rest-
less leg syndrome (RLS) and periodic leg movement syndrome 
(PLMS) are underdiagnosed in elderly demented patients due 
to inability to describe their symptoms. Patients taking selec-
tive serotonin reuptake inhibitor, antipsychotic, and other do-
pamine depleting medications may potentially develop PLMS 
as a side effect.
58 Although there is increased incidence of va-
rious sleep disturbances in demented patients, the relationship 
between sundowing and sleep abnormalities has not been stu-
died to date. Sleep studies should be done to diagnose RLS and 
PLMS in demented patients with increased daytime sleepi-
ness, and hyperkinetic parasomnias (REM sleep behavior dis-
order) which may potentially induce, imitate, or complicate 
sundown syndrome.
2 Vitiello et al.
55 reported that initial stages 
of AD are characterized by decreased time in stage 3 and 4 
non-REM sleep, as well as increased nighttime wakefulness. 
There is a tendency towards progressive REM sleep loss in 
more advanced stages of the disease.
55 Sleep disruption is not 
pathognomonic to AD, and several studies demonstrated sig-
nificant sleep disturbances in other types of dementia. In Park-
inson’s disease and Lewy body dementia sleep disruptions may 
be even more prominent than in AD.
30,55,57,58 Harper et al.
32 re-
ported that patients with frontotemporal dementia and demen-
tia related to subcortical infarcts, experience less disruption 
of nighttime sleep than in AD. Hess
3 has found that in Parkin-
son’s disease, vascular dementia, Korsakoff syndrome, and de-
pression the deterioration of sleep architecture may be promi-
nent, whereas patients with AD experienced marked hyperso-
mnolence or insomnia mostly in advanced stages of the disease. 
Other theories suggest that sleep fragmentation is important 
etiologic factor in sundowning. Bliwise et al.
56 found that awak-
enings after sunset time, spontaneous or related to nursing care, 
induced agitated behavior more frequently in demented nurs-
ing home residents.
Maladaptive response to environmental factors
Cohen-Mansfield et al.
58 studied the temporal pattern of agi-
tation and fatigue in nursing home residents with dementia. 
According to this study, only a minority of agitated nursing 
home residents, especially those with higher baseline level of 
agitation, showed increased intensity of agitation after 4:00 
PM. This finding was not in agreement with widely accepted 
notion about temporal relation between sunset period and 
peak in behavioral disruptions including agitation. Patient’s 
confusion, as a manifestation of sundowning, may be a result 
of the chronic fatigue and disturbed sleep-wake cycle.
60 After-
noon fatigue, caregiver fatigue, and overstimulation in the 
environment, as well as shifts change around 3:00 PM when 
there is more noise and general chaos, all are contributing 
factors to sundowning.
61,62 High level of activity in the morn-
ing hours and during the day may cause afternoon or even-
ing fatigue, and then lead to increased irritability and agita-
tion in demented patients.
63
Rindlisbacher and Hopkins
5 measured agitation in dement-
ed Alzheimer’s patients in terms of motor activity. Analyses 
showed that some subjects in this study demonstrated in-
creased afternoon activity, but these subjects did not corresp-
ond to nursing-assigned groups of ‘sundowners’ and ‘non-
sundowners’. Movement correlates of “sundowning” were seen 
in patients with AD presumably in the mid-stages of the de-
mentia, and less so in patients with more advanced stages of 
the disease.
5 Cohen-Mansfield et al.
11 assumed that screaming 
at night may occur in dementia patients as a response to social 
isolation. Another possible environmental contributor to sun-
downing is the lower staff-patient ratio in institutions, or le-
ssened availability of home caregivers at that time of day. It 
decreases the intensity of structured stimulation for patients, 
increases boredom, and consequently leads to agitation, rest-
lessness, and other behavioral disruptions associated behav-
ior disorder. On the other hand, with high prevalence of sun-
downing (66% among patients living at home), sundowning 
behavior in demented patient lead to inadequate, fragmented 
sleep in caregiver, and increases caregiver stress, which may 
increase the likelihood of sundowning.
26,64,65 Not surprisingly, N Khachiyants et al. 
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caregiver stress and burnout may increase the likelihood of 
institutionalization for the patient.
64,65 Staff/patient conflicts 
may arise from lack of communication, splitting staff as a re-
sult of the demented patient’s specific pathology, or frustration 
and distress due to decreased physical independence.
22 
Temporal changes in body temperature 
According to two different studies conducted by Volicer
4 
and Satlin,
20 AD causes disturbances of circadian rhythms and 
normal daily cycle of changes in body temperature, and sun-
down syndrome appears to be related to phase delay of body 
temperature, the changes that normally occur in the evening. 
Also, the patients with AD had less intense motor activity 
during the day, a higher percentage of activities during the 
night, lower interdaily stability of motor activity, and a later 
activity acrophase (time of peak) than did the healthy subjects. 
Besides that, subjects in this study had a higher mesor (fitted 
mean) temperature, higher amplitude of the fitted cosine 
temperature curve, as well as later temperature acrophase 
than did the healthy individuals. It was established that the 
severity of sundowning was associated with later acrophase 
of temperature, less correlation of circadian temperature rhy-
thm within a 24-hour cycle, and also lower amplitude of tem-
perature curve.
4 This study revealed also that “sundowning” 
patients have prone to more chaotic temperature rhythm that 
had minimal relationship to the motor activity recorded. Sat-
lin et al.
20 found that both, motor activity and body tempera-
ture rhythms had later acrophases (time of peak values). Lee 
et al.
66 examined the difference in 24-hour rhythms of sleep-
wake cycle and temperature between AD patients and elderly 
subjects as a control group. They demonstrated that the mean 
acrophase (time of peak values) and amplitudes of the two 
rhythms in the AD group were not significantly different from 
those in the control group. However, the mean phase differ-
ence between the two rhythms was significantly lower in the 
group of patients with AD than in the control group.
66
Medications as a contributing factor 
Numerous geriatricians share opinion that sundowning 
may be a side effect or the “wearing-off” effect of various me-
dications. Several drugs may induce restlessness, akathisia, or 
more serious movement disorders by causing extrapyramidal 
symptoms (antidepressants, antipsychotics). Dyskinesias may 
be secondary to on-off phenomena of anti-Parkinsonian 
drugs. Some medications may worsen cognition (e.g., through 
anticholinergic side effects).
63 It is well-known fact that virtu-
ally, any pharmacological agent, and combination of different 
medications may induce cognitive, affective, and behavioral 
changes in patients with dementia. Moreover, medications that 
are used to treat above mentioned changes may worsen pre-
viously existing pathology. Hypnotics, benzodiazepines, and 
low-potency antipsychotics are among conventional therapy 
that used to manage evening agitation and behavioral disrup-
tions associated with sundowning. Side-effects of such medi-
cations, including akathisia, tardive dyskinesia, muscle rigidi-
ty, anticholinergic toxicity (tachycardia, constipation, and con-
fusion), orthostatic hypotension, and others may further con-
tribute to development of sundowning in demented patients. 
Widely used benzodiazepines and other hypnotics to control 
nocturnal agitation, are considered to be a poor drugs of ch-
oice for elderly patients who often have several comorbidities. 
They tend to create drug tolerance, dependence, withdrawal, 
and even significantly increase the risk of respiratory and cen-
tral nervous system depression. These drugs may cause para-
doxical agitation, increase disinhibition and confusion in el-
derly patients with preexisting agitation who have sundowning 
syndrome.
22 
Medical and psychiatric conditions as a contributing 
factor 
A vast variety of medical factors can contribute to temporal-
ly associated agitation. For example, some diseases in which 
pain is intense may initiate or worsen cognitive, affective, or 
behavioral disturbances in the late afternoon. Bachman et al.
63 
reported that agitation may be a manifestation of the response 
to temporal variation in pain. Mood variability in some de-
mented patients may have predictable pattern, and in major 
depression worsening of mood in the evening hours (which 
may characterize atypical pattern of major depression), might 
possibly explain some cases of sundowning.
63 It can be hypo-
thesized that agitation and changes in activity in demented 
patients with depression may be manifested as sundowning; 
taking into consideration difficulties in eliciting other symp-
toms of depression in cognitively impaired individuals.
63 Some 
researchers theorize that hunger, changes in blood glucose 
levels after eating in patients with diabetes, or a drop in blood 
pressure after a meal (which temporarily deprives brain from 
oxygen), may bring on agitation and confusion in susceptible 
individuals.
67 
Diagnosis
Diagnosis of sundown syndrome is purely clinical, and ch-
aracterized by wide variety of cognitive, affective, and behav-
ioral abnormalities which all have temporal pattern with symp-
tom emergence or worsening in late afternoon, at evening, or 
at night. There has not been found any data on specific labo-
ratory findings, imaging studies, or electrophysiologic stud-
ies in sundown syndrome in researched medical literature. It 
is not intent of this literature review to provide a comprehensive 
search specifically on diagnosis of sundowning syndrome.280  Psychiatry Investig 2011;8:275-287
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Differential diagnosis
A major difference between sundowning and delirium will 
be that delirium tends to be relatively acute in onset, relatively 
brief (a matter of hours or days), and fluctuating in the course 
of the day. Although fluctuating, delirium will not share the 
pattern of fluctuation characterized for sundowning, when 
prominent onset and exacerbation of cognitive and behavior-
al disruption brought on by late afternoon, early evening, or 
night hours. Therefore, the cardinal differentiation between 
delirium and sundowning is supposed to be made in terms 
of temporal characteristics, and primarily, on the basis of the 
onset and termination. It is not known to date, whether the 
pathophysiological mechanisms involved with the demented 
patient in the onset of sundowning are the identical or at least 
similar to delirium.
68,69 In majority of cases, patients already 
have some degree of medical or cognitive compromise prior 
to the development of sundowning. Moreover, in demented 
patients there is always a possibility of delirium due to various 
medical reasons, and there is a great challenge for clinician to 
differentiate delirium due to medical condition from sundown-
ing in cognitively compromised patients. It was suggested 
that delirium may be a pre-condition for nocturnal delirium. 
In respect to differentiation between delirium, and sundown-
ing, Duckett
22 stated that dementia may in fact be a necessary 
but not a sufficient condition: not all demented patients sun-
down, but virtually all sundowning patients are demented, as 
well as delirious at the time of their sundowning episode. 
Treatment
Both non-pharmacologic and pharmacologic approaches 
have been considered in the treatment of patients with sun-
downing. According to the reviewed literature, among medi-
cal factors which may contribute to sundowning in the elderly 
individuals with dementia are: chronic pain syndrome due to 
arthritis and malignancy, organ systemic disorders (including 
congestive heart failure, ischemic heart disease, asthma, chro-
nic obstructive pulmonary disease, gastroesophageal reflux, 
incontinence, benign prostatic hypertrophy), psychiatric con-
ditions (including depression, anxiety, psychosis), and effects 
of various medications.
19,63,70 In demented patients, physical dis-
comfort and illness may also be expressed as behavioral ab-
normalities. Individuals with AD are not able to react to pain 
or other physical discomfort in standard ways, as well as to 
relate to their body properly. That is why elderly demented 
patients often use aggression and other behaviors, such as 
yelling, screaming and refusing to eat to express pain or other 
physical symptoms. It was suggested to use “S-M-A-R-T”
71 or 
“P.I.E.C.E.S.”
72 approaches in management of dementia-relat-
ed behavioral problems. The former includes Safety, medical 
work-up, assessment of competency, rest/review of causes of 
behavioral abnormalities, and trial of medications. The latter 
includes considering physical problems, Intellectual/cogni-
tive changes, emotional problems, capabilities, environment, 
social/cultural issues. Considering sundowning symptoms be-
ing a part of behavioral and psychological symptoms of de-
mentia, it is reasonable to use the same “S-M-A-R-T” or “P.
I.E.C.E.S” approaches in complex treatment of behavioral ma-
nifestations of sundown syndrome. Therefore, before consider-
ing any specific treatment for sundown syndrome in elderly 
demented patients, it is reasonable to gather a careful history, 
perform thorough physical examination, and laboratory in-
vestigations in order to evaluate a patient for temporal pat-
terns of agitation and other manifestations of sundowning 
syndrome, and its possible connection to various medical con-
ditions. According to data from current medical literature, the 
following interventions have been tried and found to be some-
what effective for the treatment of sundowning in demented 
patients: bright light therapy, melatonin, acetylcholinesterase 
inhibitors, antipsychotic medications, and environmental in-
tervention/ behavioral modifications. 
Light therapy 
One of the environmental modifications that have been sug-
gested by several researchers for empirical treatment of sun-
downing syndrome is light therapy.
73-82 
A review of the available ambient light in the patient’s room 
demonstrated that in different portions of the hospital there 
was a significant difference in available light that was not im-
mediately obvious to the healthy eye.
22 Increased amount of 
lighting in the evening hours may considerably assist the el-
derly patient with neurologically compromised brain in re-ori-
enting.
73 It was suggested by Duckett
22 to modify ambient light 
by matching light readings obtained from the day and even-
ing hours. 
It was reported that the placing a full-spectrum fluorescent 
lamp (between 2,500 and 5,000 lux) about 1 meter from the 
sundowning patient within his or her visual field for a couple 
of hours in the morning may change the patient’s circadian 
rhythm, and make demented individual less agitated at con-
fused. It may be achieved by turning light on while the patient 
is watching television or doing other daily activities.
74 In one 
study, the patients suffering from AD, sundown syndrome, 
and difficulties with sleep maintenance that were treated with 
bright light, have demonstrated improved sleep quality and 
less sundowning episodes.
75-77 In another study, Murphy and 
Campbell
78 have found that during the exposure to bright light 
there was progression in cognitive functioning in elderly in-
dividuals. In a 6-week, double-blind, placebo-controlled, cross-
over trial the effects of bright light therapy combined with 
melatonin on motor restless behavior in demented patients N Khachiyants et al. 
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had been evaluated.
79 This study concluded that bright light 
therapy (10,000 lux bright light) has a positive effect on mo-
tor restlessness in subjects with dementia. A review of the Co-
chrane meta-analysis related to light therapy for managing 
sleep, behavior, and mood disturbances in dementia did not 
demonstrate the effectiveness of specific light therapy.
80 Oka-
wa et al.
81 reported positive effect of phototherapy on sleep-
wake disorders in elderly demented patients. Another report 
demonstrated that treatment with bright light improved agi-
tated behavior in institutionalized elderly patients.
82 
Melatonin
Several studies suggested that circadian rhythm disruptions 
in individuals with dementia have been linked to decreased or 
dysregulated melatonin level and abnormalities in the SCN 
in this patient population, and possibly related to development 
of sundowning behavior.
4,20,29-34,83-88 These studies served as a 
rationale for the treatment of circadian rhythm- related beha-
vioral problem such as sundowning with melatonin. A sys-
tematic review of literature related to treatment of elderly pa-
tients with insomnia (1990-2000) revealed 12 studies with 
empirical treatment results for melatonin in the elderly.
89 Am-
ong these 12 studies, 6 double-blind controlled trials analyz-
ed results by objective measurements of sleep quality. Decre-
ase in sleep latency was registered in 4 studies. Three double-
blind controlled trials found improvement in such objective 
characteristics of sleep quality as total sleep time, sleep effici-
ency, and wake time during sleep) as a result of melatonin treat-
ment, although there was no improvement in subjective sleep 
quality. Another 6 open-label or retrospective case studies sh-
owed a trend toward decreased sundowning and improved 
sleep quality.
90 Several recent studies which reflect use of me-
latonin specifically in patients with dementia, demonstrated 
that melatonin reduces sundowning behavior, nocturnal ac-
tivity, decreases sleep latency, and improves quality of sleep.
89-91 
De Jonghe et al.
47 performed a systematic search of the litera-
ture related to melatonin treatment in dementia which was 
published between 1985 and 2009. Four randomized con-
trolled trials (RCTs), including 243 participants, and five case 
series including 87 participants have been analyzed. Two of 
the RCTs demonstrated a remarkable improvement of agita-
tion and other manifestations of sundowning syndrome. Im-
provement of sundowning behavior was reported in all five 
case series. Based on this literature review, the effect of melato-
nin treatment on sleep quality and daytime functioning were 
inconclusive.
47 Cohen-Mansfield et al.
48 in a pilot study inves-
tigated the effect of melatonin treatment on improving sleep 
and reducing sundowning in 11 demented elderly nursing 
home residents. Results of this study showed a significant de-
crease in agitated behaviors during the day, as well as marked 
decrease in daytime sleepiness in subjects after treatment with 
melatonin. There was a slight decrease in sleep latency in the 
evening hours. The night-time sleep ratings were not remark-
ably changed in these patients.
48 Although Haffmans et al.
79 de-
monstrated that bright light therapy (10,000 lux bright light) 
has a positive effect on motor restlessness in demented pa-
tients, combination of melatonin with bright light does not re-
sult in any improvement of motor restless behavior in this pa-
tient population. Authors of this study hypothesized that com-
bination of two zeitgebers (bright light and melatonin) may 
be “too much” in regulation of disruptive behavior. Also, it was 
possible that melatonin has very little effect on regulation of 
abnormal behavior in demented subjects. In accordance to 
this result, Rao et al.
92 found that treatment with bright light 
modifies the circadian melatonin profile of depressed pa-
tients and healthy controls only minimally. Singer et al.
93 ana-
lyzed effect of melatonin on sleep disturbances in patients 
with AD in a double-blind placebo-controlled study of 36 
centers with 156 nursing home subjects. He did not find any 
benefits of melatonin for treatment of insomnia in studied 
subjects. Therefore, based on this literature review, there is no 
conclusive date related to effectiveness of melatonin treatment 
for sundowning in demented patients.
Acetylcholinesterase inhibitors 
Although acetylcholinesterase inhibitors (AChEIs) are the 
standard of treatment of mild and moderate AD in the Unit-
ed States, there is no clear evidence of their benefit in control-
ling behavioral symptoms, including sundowning. Data re-
lated to effect of different AChEIs on sundowning behavior 
are limited, and contradictory to date. Ross et al.
94 and Rogers 
et al.
95 suggested that donepezil might worsen nocturnal agi-
tation and other behavioral disruptions in demented patients 
at night by inducing insomnia or nightmares. Rogers et al.
95 
also demonstrated that 10% of patients who were treated with 
donepezil experienced insomnia. Insomnia as a side effect 
may be less prominent with galantamine and rivastigmine 
than with donepezil.
96,97 Nevertheless, no differences have 
been demonstrated in sleep measures between the galanta-
mine and placebo in the evaluation of subjects using the Pitts-
burg Sleep Quality Index.
96 There was recommendation to 
attenuate adverse effects of donepezil on sleep by slow dose 
escalation tapering, as well as by switching evening dose to 
morning dose.
98 Another study showed that donepezil given 
once a day in the morning has increased sleep efficiency and 
shortened sleep latency.
99 Several reports have described the 
effect of donepezil and other AChEIs on cognitive function, 
behavioral abnormalities, and sundowning in dementia with 
Lewy Bodies.
100-102 Skjerve et al.
100 reported an improvement in 
sundowning symptoms in 71-year-old man with clinically di-282  Psychiatry Investig 2011;8:275-287
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agnosed dementia with Lewy bodies after treatment with 
donepezil. The positive results of the treatment included a ma-
rked reduction in evening activity and increase in daytime ac-
tivity, as measured using the activity electronic monitoring te-
chnique, along with improved cognition and Parkinsonism.
100 
MacLean et al.
102 reported decreased dreaming behavior in 
Lewy body dementia patients treated with rivastigmine. An-
other open-label trial showed improvement of cognitive func-
tioning and psychosis in patient with Parkinson’s disease as a 
result of treatment with rivastigmine.
103 Stahl et al.
104 evaluated 
results from three randomized double-blind trials of galanta-
mine versus placebo in AD. They revealed no increase in inso-
mnia or other sleep problems and nightmares but no reduc-
tion in sleep disturbances.
104 Recent multiple RCTs demon-
strated positive impact of galantamine,
105 rivastigmine,
106-108 
and donepezil
109-111 on behavioral and psychological symp-
toms of dementia, although they did not address specifically 
effect of above medications on sundowning symptoms. Cur-
rently, there is no specific data are available on treatment of sun-
downing syndrome with N-methyl-d-aspartate (NMDA) re-
ceptor antagonist memantine. Most of the studies are address-
ing common behavioral abnormalities, agitation, aggression, 
and psychosis in patients with AD
112 However, Forchetti
113 dis-
agrees with using memantine to modify behavior, because 
the clinical trials did not demonstrate a significant effect on 
the Neuropsychiatric Inventory, the instrument used to mea-
sure changes in behavioral symptoms. 
Antipsychotic medications
Although antipsychotics are probably the most widely used 
class of medications to manage symptoms of sundowning, 
there is limited information available in the medical litera-
ture on this particular topic. Majority of studies are reflecting 
use of antipsychotic medications in demented individuals for 
various behavioral disruptions, including psychosis and agi-
tation, but not specifically for sundowning.
114-129 Stoope et al.
114 
reported that >40% of family practitioners and neuropsychi-
atrists in Germany considered antipsychotic medications to 
be the drugs of choice for treatment of sundowning and oth-
er sleep disturbances in elderly demented patients. Numer-
ous RCTs are supported the effectiveness of several antipsy-
chotic medications (risperidone, olanzapine, aripiprazole) for 
the treatment of behavioral symptoms in dementia.
119-123 An-
other report reflected the use of quetiapine for behavioral dis-
ruptions and psychosis in nursing home residents with AD.
124 
The Clinical Antipsychotic Trials of Intervention Effective-
ness-Alzheimer’s Disease demonstrated that atypical antipsy-
chotic use was associated with marked improvement in para-
noid ideations, aggression, and anger.
127 Tariot
115 reported that 
antipsychotic medications exhibit modest effects on agitation 
in patients with severe dementia with only 15-20% effect size 
over placebo. He also demonstrated that about one third of 
patients on antipsychotic medications may experience mild 
sedation, which may be favorable in sleep facilitation. Another 
study suggested antipsychotic medications for treatment of 
various sleep disturbances and maladaptive behaviors at night-
time in severely demented nursing home residents.
121 It was 
reported that there was even slight effect of antipsychotic treat-
ment on daytime agitation, and after discontinuation of anti-
psychotic medications for four weeks, the global behavioral sc-
ores remained relatively stable or improved in majority of sub-
jects.
116 Standbridge
128 suggested atypical antipsychotics for the 
treatment of sundowning and confusion in the evening, due 
to their sedative side effects. Parnetti
129 demonstrated that aty-
pical antipsychotics at very low dosages can be used to treat 
delusions, hallucinations, and paranoid ideations. Atypical an-
tipsychotics, comparing to typical antipsychotics, have more 
favorable side-effect profile.
2 Nevertheless, its use should be 
carefully weighed against such life-threatening side effects as 
pneumonia, stroke, and death.
130-132 Risperidone, is one of the 
commonly used agent, has been shown to decrease noctur-
nal agitation in nursing home residents.
118 Another study de-
monstrated reduction of aggressiveness and wandering, as well 
as increase nighttime sleeping hours in demented patients 
treated with risperidone.
117 It was recommended to reassess 
cognitive and behavioral status of demented patients on anti-
psychotic medications on a regular basis: within 3 months af-
ter treatment initiation (Canadian treatment guidelines),
133 or 
at least every 3 to 6 months if they are outpatients.
128,129 While 
there are no specific studies related to use of atypical antipsy-
chotics for the treatment of sundowning, they might be con-
sidered as effective medications for this purposes, especially 
because these drugs are better tolerated than typical antipsy-
chotics in the elderly patients.
2
Environmental interventions/Behavioral modifications 
Results from the studies related to behavioral interventions 
for management of neurpsychiatric symptoms of dementia are 
inconsistent. Although it has been difficult to validate effec-
tiveness of specific therapies for sundowning syndrome, sev-
eral clinical observations has led to the emergence of various 
recommendations and intervention strategies. Different clini-
cians agree on these strategies that empirically support their 
usefulness.
62 Individually tailored non-pharmacological ap-
proaches for management of behavioral disruptions, includ-
ing sundowning, considered to be the first-line therapy, and sh-
ould be attempted before pharmacologic interventions.
133,134 
The following management options has been suggested as pos-
sible interventions for behavioral abnormalities in dementia, 
which theoretically might be effective for sundowning as well: N Khachiyants et al. 
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light therapy,
73-82,135 music therapy,
136 aromatherapy,
137 caregi-
ver education,
138 multisensory stimulation,
139 and simulated pres-
ence therapy.
140 Other recommendations include reduction of 
noisy background, minimizing unnecessary noise (e.g., noise 
from visitors, loud speakers, banging of dishes, loud staff con-
versation), offering simple instructions for meals and bath-
ing, adherence to a stable daily routine.
2,62,63,141 More detailed 
information about a non-pharmacologic management of beha-
vioral disruptions in AD can be found in the recently reported 
findings of the Resources for Advancing Alzheimer’s Care-
giver’s Health (REACH) trial, the largest randomized controll-
ed clinical trial to date, involving 1222 caregiver and care re-
cipients recruited from 6 different sites in the United States.
74   
Several clinicians suggest that involvement of demented pa-
tients in structured, planned activities may reduce likelihood 
of behavioral disruptions, including agitation, especially if 
these activities specifically scheduled at the times of agita-
tion, or before beginning of behavioral abnormalities.
2,62 It was 
recommended to follow sleep hygiene routine, try to keep de-
mented patient mentally occupied during the day, adhere to 
a structured daily schedule, and provide opportunities for phy-
sical exercise.
141 Meeting physical needs, addressing pain, dy-
skinesias, constipation, and other physical discomfort is cru-
cial in preventing agitation, confusion, and other behavioral 
disturbances in demented patients.
63 Redirection, reassurance, 
and distraction as clinical tools, can be learned by nursing staff 
and caregivers, and should be included in treatment plan.
63 It 
was strongly recommended for caregivers to monitor televi-
sion-viewing by demented patients, especially during evening 
hours. Some frightening or violent events depicted on televi-
sion, may be very stressful and disturbing for cognitively im-
paired individuals, as they may believe that these events are 
actually happening to them in reality. As a result, these pati-
ents may express their fears in the form of agitation, confusion, 
or violence.
113 Creation of relaxing environment is another use-
ful tool to ease sundown syndrome in demented patients. Li-
stening CD with favorite music, sounds of nature (ocean waves, 
bird’s songs, or mountain stream) might relax and calm pa-
tient down. In case of agitation due to hunger, or thirst, just 
offering a food, snack or something to drink may ease dis-
comfort and reduce behavioral disruption. Talking to the pa-
tient with soft, calm voice, doing hand massage, or just hold-
ing his hand may reassure patient and diminish anxiety.
74   
Other general recommendations include management of de-
pression, feelings of guilt, sadness, grief, feelings of worthless-
ness, anxiety and frustration. It may also be provoked by con-
fusion related to cognitive impairment, and induce agitation, 
sleep disturbances, which all may contribute to emergence or 
worsening of sundowning.
113
Prognosis
There has been very little research data on prognosis of the 
sundown syndrome. Scarmeas et al.
25 reported that the pres-
ence of sundown syndrome has been associated with more ra-
pid cognitive function deterioration in patients with early st-
ages of AD.
Prevention
Exploration of potential etiologic factors of sundowning syn-
drome (environmental, physiological, psychological) in each 
demented individual, as well as addressing modifiable factors 
with appropriate interventions, seems to be the best way to pre-
vent clinical symptoms of sundowning. There is limited data 
in current medical literature on effective methods of preven-
tion of sundowning syndrome in dementia. Nevertheless, it 
might be hypothesized, that several interventions that have 
been used to treat sundowning syndrome, may have been 
considered in prevention of this clinical phenomena. These 
interventions are as follows: environmental interventions/ be-
havioral modifications as a first line treatment,
133,134 including 
light therapy,
73-82,135 music therapy,
136 aromatherapy,
137 caregiv-
er education,
138 multisensory stimulation,
139 and simulated 
presence therapy,
140 following sleep hygiene routine, adher-
ence to a structured daily schedule, and physical exercise.
141 
There is no clear evidence that prophylactic use of melatonin, 
AChEIs, or NMDA receptor antagonist is effective in preven-
tion of sundown syndrome development in dementia.
CONCLUSION
Factors underlying clinical manifestations of sundowning 
are usually multifaceted, and requiring biopsychosocial ap-
proaches to assessment and treatment. Various behavioral dis-
ruptions, including sundowning syndrome in AD and other 
types of dementia, have become an increasingly important 
topic of clinical investigations. The emergence or worsening 
of behavioral disturbances in cognitively impaired individu-
als has been recognized by clinicians for the last several de-
cades, which prompted researchers to utilize different meth-
ods to investigate the circadian rhythm, hormonal, physio-
logical, pharmacological, iatrogenic, psychological, and other 
possible correlations with sundowning symptoms. Frequent-
ly observed behavioral abnormalities in demented patients 
with exacerbation in the late afternoon, evening, or at night, 
pose a significant burden and challenge to caregivers, families, 
and nursing staff. Finding complex etiological relationships 
between triggering factors and various manifestations of sun-
downing syndrome may lead to effective management of this 
clinical phenomenon.284  Psychiatry Investig 2011;8:275-287
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